Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter
TG Therapeutics (TGTX)
In a report released today, Brian Cheng from J.P. Morgan reiterated a Buy rating on TG Therapeutics. The company’s shares closed last Wednesday at $39.20, close to its 52-week high of $43.32.
According to TipRanks.com, Cheng is a 4-star analyst with an average return of 6.0% and a 50.7% success rate. Cheng covers the Healthcare sector, focusing on stocks such as Ascentage Pharma Group International Unsponsored ADR, Kyverna Therapeutics, Inc., and Arrowhead Pharmaceuticals.
Currently, the analyst consensus on TG Therapeutics is a Hold with an average price target of $44.25, which is a 9.9% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $70.00 price target.
